Aligos Therapeutics GAAP EPS of -$0.51 misses by $0.02, revenue of $3.54M beats by $1.39M
- Aligos Therapeutics press release (NASDAQ:ALGS): Q4 GAAP EPS of -$0.51 misses by $0.02.
- Revenue of $3.54M (+856.8% Y/Y) beats by $1.39M.
- Cash, cash equivalents and investments totaled $125.8 million as of December 31, 2022, compared with $205.8 million as of December 31, 2021.
- ALGS continues to believe its cash balance provides sufficient cash to fund planned operations through the end of 2024.